These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 22378083)

  • 1. Discriminant analysis of malignant mesothelioma and reactive mesothelium using three-dimensional nuclear estimation.
    Washiya K; Narumi K; Noro T; Hamakawa S; Furuta N; Yoshioka H; Watanabe J
    Acta Cytol; 2012; 56(2):189-95. PubMed ID: 22378083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminant analysis between malignant mesothelioma and reactive mesothelium using nuclear three-dimensional analysis is useful for morphologically suspicious cases.
    Washiya K; Mizuki Y; Nakamura M; Kakinuma H; Saegusa M; Satoh Y; Yoshioka H; Watanabe J
    Acta Cytol; 2013; 57(5):509-15. PubMed ID: 24021244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of discriminant analysis using nuclear three-dimensional analysis in atypical cells prepared from bronchial brushing cytology cases that are cytologically challenging.
    Washiya K; Noro T; Narumi K; Kurose A; Yoshioka H; Watanabe J
    Acta Cytol; 2012; 56(3):297-303. PubMed ID: 22555533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA).
    Ramael M; Jacobs W; Weyler J; Van Meerbeeck J; Białasiewicz P; Van den Bossche J; Buysse C; Vermeire P; Van Marck E
    J Pathol; 1994 Mar; 172(3):247-53. PubMed ID: 7910850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
    Shin HJ; Shin DM; Tarco E; Sneige N
    Cancer; 2003 Aug; 99(4):233-9. PubMed ID: 12925985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A morphometrically-based classification rule for the diagnosis of primary mesothelial lesions.
    Robutti F; Betta PG; Donna A; Pavesi M
    J Pathol; 1990 Sep; 162(1):57-60. PubMed ID: 2231194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.
    Aerts JG; Delahaye M; van der Kwast TH; Davidson B; Hoogsteden HC; van Meerbeeck JP
    Diagn Cytopathol; 2006 Aug; 34(8):523-7. PubMed ID: 16850492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method.
    Hofman V; Long E; Ilie M; Bonnetaud C; Vignaud JM; Fléjou JF; Lantuejoul S; Piaton E; Mourad N; Butori C; Selva E; Marquette CH; Poudenx M; Sibon S; Kelhef S; Vénissac N; Jais JP; Mouroux J; Molina TJ; Vielh P; Hofman P
    Cytopathology; 2012 Feb; 23(1):30-8. PubMed ID: 21210876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
    Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
    Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long microvilli of mesothelioma are conspicuous in pleural effusions processed by Ultrafast Papanicolaou stain.
    Yang GC
    Cancer; 2003 Feb; 99(1):17-22. PubMed ID: 12589641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine needle aspiration cytology of malignant mesothelioma.
    Sterrett GF; Whitaker D; Shilkin KB; Walters MN
    Acta Cytol; 1987; 31(2):185-93. PubMed ID: 3469852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mesothelium and malignant mesothelioma of the pericardium].
    Likhachev IuP; Baldin DG; Zaĭtseva NK; Seliuzhitskiĭ IV; Zhuravlev AP
    Arkh Patol; 1999; 61(2):11-5. PubMed ID: 10412581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
    Lovrenski A; Panjković M; Tegeltija D; Latinović LT; Krcedinac J
    Med Pregl; 2012; 65(1-2):5-8. PubMed ID: 22452231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
    Saad RS; Cho P; Liu YL; Silverman JF
    Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.